REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

Cancer treatments that couple pharmacological activation of tumor antigen presentation with activation and expansion of CD8+ T and natural killer (NK) cells in the tumor environment have the potential to induce an effective anti-tumor immune response in patients. NKTR-262 is a small molecule agonist of toll-like receptors (TLRs) 7/8 designed to be retained in the tumor micro-environment in order to activate antigen-presenting cells (APC), such as dendritic cells, to create new antigen-specific cytotoxic T cells. As a CD122-biased agonist, bempegaldesleukin monotherapy increases newly proliferative CD8+ T cells in tumors. NKTR-262 plus bempegaldesleukin is expected to increase expansion of antigen-specific CD8+ T cells. In preclinical studies, a single IT injection of NKTR-262 plus IV bempegaldesleukin resulted in complete abscopal effects in tumor models. Preliminary clinical data show bempegaldesleukin plus nivolumab enhances immune-stimulatory responses. The REVEAL trial will assess safety and anti-tumor activity of NKTR-262 with bempegaldesleukin +/- nivolumab for the treatment of selected cancers. * Melanoma (1st-line and relapsed/refractory) * Merkel Cell Carcinoma (2nd-line and relapsed/refractory) * Triple Negative Breast Cancer (1st- and 2nd-line and relapsed/refractory) * Renal Cell Carcinoma (1st-line and relapsed/refractory) * Colorectal Cancer (2nd-line and relapsed/refractory; MSI non-high) * Colorectal Cancer (2nd 3rd-line+, I-O therapy naive; relapsed/refractory; MSI high) * Head and Neck Squamous Cell Carcinoma (2nd-line and relapsed/refractory) * Sarcoma (2nd-line and relapsed/refractory)